Availability of Multiple Myeloma Investigations in Nepal
Most essential investigations for multiple myeloma are available in Nepal, but primarily in major tertiary care centers in Kathmandu, with significant limitations in advanced diagnostic capabilities and substantial out-of-pocket costs for patients.
Basic Laboratory Tests - Widely Available
The fundamental investigations needed for multiple myeloma diagnosis are available at major hospitals in Nepal 1, 2:
- Complete blood count (CBC) with differential
- Chemistry panel (calcium, creatinine, electrolytes, liver function tests)
- Serum albumin
- Lactate dehydrogenase (LDH)
- Beta-2 microglobulin
- Routine urinalysis
- 24-hour urine collection for total protein
These basic tests can be performed at teaching hospitals in Kathmandu and some regional centers.
Critical Diagnostic Tests - Limited Availability
The most important specialized tests face significant accessibility challenges 3:
Protein Studies (Essential for Diagnosis)
- Serum protein electrophoresis (SPEP) - Unavailable in public hospitals in 62.5% of South Asian countries including Nepal
- Serum immunofixation (SIFE) - Similarly limited in public sector
- Urine protein electrophoresis (UPEP) and immunofixation (UIFE) - Restricted availability
- Serum free light chain assay - Unavailable in public hospitals in 62.5% of countries; must be obtained through private laboratories at significant cost
Where available: These tests are primarily accessible at:
- Private laboratories in Kathmandu
- Select tertiary care centers (Tribhuvan University Teaching Hospital, B.P. Koirala Memorial Cancer Hospital)
- Patients often must send samples to India for processing 3, 4
Bone Marrow Evaluation - Available but Limited
Bone marrow aspirate and biopsy can be performed at major teaching hospitals 1, 2:
- Available at tertiary centers in Kathmandu
- CD138 staining for accurate plasma cell quantification has limited availability
- Immunoperoxidase or immunofluorescence for clonality assessment is not routinely available
Advanced Cytogenetic Testing - Severely Limited
Critical prognostic tests are largely unavailable 1, 3:
- Metaphase cytogenetics - Very limited availability
- FISH testing (for chromosome 17p13, t(4;14), t(14;16)) - Not available in public institutions; extremely limited in private sector
- Minimal residual disease (MRD) estimation by flow cytometry - Not available in Nepal (available only in India among South Asian countries)
Imaging Studies - Variable Availability
Available:
- Plain radiographic skeletal survey - Widely available at major hospitals 1
- CT scans - Available at tertiary centers in Kathmandu
Limited/Expensive:
- MRI - Available but cost-prohibitive for most patients 3
- PET-CT - Not available in public hospitals; extremely limited private availability and prohibitively expensive 3
Major Practical Barriers
Financial Burden
Patients face approximately 70% out-of-pocket expenditure for multiple myeloma investigations and treatment 3. This represents a catastrophic financial burden for most Nepali families.
Geographic Concentration
- Nearly all specialized testing is concentrated in Kathmandu
- Patients from rural areas must travel to the capital
- No comprehensive myeloma diagnostic center exists 4
Quality Control Issues
Laboratory quality control and standardization remain problematic 4:
- No effective national quality monitoring system
- Variable reliability of test results
- Lack of mandatory licensing for clinical pathology laboratories
Recommended Approach for Nepali Patients
For initial workup, prioritize these investigations that can be obtained locally 1, 2:
- CBC, chemistry panel, calcium, creatinine - Any major hospital
- Serum and urine protein studies - Private laboratories in Kathmandu (expect significant cost)
- Bone marrow examination - Tertiary care centers
- Skeletal survey - Major hospitals with radiology departments
- Beta-2 microglobulin and LDH - Available at teaching hospitals
For advanced testing (FISH, MRD assessment), patients typically require:
- Referral to private laboratories with international partnerships
- Consideration of sending samples to India
- Substantial financial resources (often requiring fundraising or medical loans)
Critical Caveat
The absence of serum free light chain assay and FISH testing in most Nepali institutions means that accurate risk stratification and optimal treatment planning are compromised 1, 2. This directly impacts patient outcomes, as these tests guide critical treatment decisions including transplant eligibility and choice of therapy regimens.
Without minimal residual disease monitoring capability, assessment of treatment response and decisions about maintenance therapy are based on less sensitive methods, potentially affecting long-term survival 2, 3.